


## Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Claim 1. (cancelled)

Claim 2. (previously presented) A method according to claim 65, wherein



Claim 3. (previously presented) A method according to claim 2, wherein W is optionally substituted heteroaryl.

Claim 4. (Currently Amended) A method according to claim 3, wherein W is pyridyl, pyrimidinyl, pyridizinyl, pyrrolyl, imidazolyl, pyrazolyl or thiophenyl, each of which is optionally substituted with up to ~~5~~ 4 groups independently selected from hydrogen, halogen, hydroxy, amino, mono- or di(C<sub>1</sub>-C<sub>6</sub>)alkyl amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy.

Claim 5. (previously presented) A method according to claim 2, wherein W is optionally substituted aryl.

Claim 6. (previously presented) A method according to claim 5, wherein W is phenyl optionally substituted with up to 5 groups independently selected from hydrogen, halogen, hydroxy,

amino, mono- or di(C<sub>1</sub>-C<sub>6</sub>)alkyl amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy.

Claim 7. (previously presented) A method according to claim 6, wherein

R<sub>4</sub> and R<sub>5</sub> are independently C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 1 or 2 substituents independently chosen from halogen, hydroxy, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, phenyl, pyridyl, and pyrimidyl, wherein each of phenyl, pyridyl, and pyrimidyl is optionally substituted with up to three groups independently selected from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy and amino.

Claim 8. (previously presented) A method according to claim 6, wherein

R<sub>1</sub> and R<sub>2</sub> are independently chosen from hydrogen, halogen, hydroxy, amino, mono- and di(C<sub>1</sub>-C<sub>6</sub>)alkyl amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy; and R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently C<sub>1</sub>-C<sub>6</sub> alkyl.

Claim 9. (previously presented) A method according to claim 6, wherein


R<sub>1</sub> and R<sub>2</sub> together with the atoms with which they are attached form a partially saturated or unsaturated carbocyclic ring of from 3 to 8 carbon atoms, wherein the ring is optionally substituted by up to 5 substituents independently chosen from halogen, hydroxy, amino, mono- and di(C<sub>1</sub>-C<sub>6</sub>)alkyl amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy; and

R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently H or C<sub>1</sub>-C<sub>6</sub> alkyl.

Claim 10. (previously presented) A method according to claim 9, wherein

R<sub>1</sub> and R<sub>2</sub> together with the atoms with which they are attached form a cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, cycloheptadienyl, phenyl, cyclooctadienyl, and cyclooctenyl, wherein each ring is optionally substituted by up to 5 substituents independently chosen from halogen, hydroxy, amino, mono- and di(C<sub>1</sub>-C<sub>6</sub>)alkyl amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy; and R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently C<sub>1</sub>-C<sub>4</sub> alkyl.

Claim 11. (previously presented) A method according to claim 65, where the compound has the formula:



or a pharmaceutically acceptable salt thereof, wherein:

n is 1, 2, or 3;

R<sub>1</sub> and R<sub>2</sub> are independently chosen from hydrogen, halogen, hydroxy, amino, mono- and di(C<sub>1</sub>-C<sub>6</sub>)alkyl amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy; or


R<sub>1</sub> and R<sub>2</sub> together with the atoms with which they are attached form a partially saturated or unsaturated carbocyclic ring of from 3 to 8 carbon atoms, wherein the ring is optionally substituted by up to 5 substituents independently chosen from halogen, hydroxy, amino, mono- and di(C<sub>1</sub>-C<sub>6</sub>)alkyl amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy;

$R_3$ ,  $R_4$  and  $R_5$  are independently chosen from (i) hydrogen; and (ii)  $C_1$ - $C_6$  acyl and  $C_1$ - $C_6$  alkyl, optionally substituted with up to three substituents independently chosen from halogen, hydroxy, halo( $C_1$ - $C_2$ )alkyl, halo( $C_1$ - $C_2$ )alkoxy, methoxy, ethoxy,  $C_3$ - $C_7$  cycloalkyl, phenyl, pyridyl and pyrimidyl, wherein each of phenyl, pyridyl and pyrimidyl is optionally substituted with up to three groups selected independently from halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, hydroxy and amino;

$R_6$  and  $R_6'$  are independently selected at each occurrence from hydrogen and  $C_1$ - $C_6$  alkyl; and

$R_{10}$ ,  $R_{11}$ , X, Y and Z are independently selected from hydrogen, halogen, hydroxy, amino, mono- and di( $C_1$ - $C_6$ )alkyl amino, halo( $C_1$ - $C_6$ )alkyl, halo( $C_1$ - $C_6$ )alkoxy,  $C_1$ - $C_6$  alkyl and  $C_1$ - $C_6$  alkoxy.

Claim 12. (previously presented) A method according to claim 65, where the compound has the formula:



or a pharmaceutically acceptable salt thereof, wherein:

$n$  is 1, 2, or 3;

$R_1$  and  $R_2$  are independently chosen from hydrogen, halogen, hydroxy, amino, mono- and di( $C_1$ - $C_6$ )alkyl amino, halo( $C_1$ - $C_6$ )alkyl, halo( $C_1$ - $C_6$ )alkoxy,  $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkoxy, or

$R_1$  and  $R_2$  together with the atoms with which they are attached form a partially saturated or unsaturated carbocyclic ring of from 3 to 8 carbon atoms, wherein the ring is optionally substituted by up to 5 substituents independently chosen from halogen, hydroxy, amino, mono- and di( $C_1$ - $C_6$ )alkyl amino,


halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy;

R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently chosen from (i) hydrogen; and (ii) C<sub>1</sub>-C<sub>6</sub> acyl and C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted with up to three substituents independently chosen from halogen, hydroxy, halo(C<sub>1</sub>-C<sub>2</sub>)alkyl, halo(C<sub>1</sub>-C<sub>2</sub>)alkoxy, methoxy, ethoxy, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, phenyl, pyridyl and pyrimidyl, wherein each of phenyl, pyridyl and pyrimidyl is optionally substituted with up to three groups selected independently from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy and amino;

R<sub>6</sub> and R<sub>6</sub>' are independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>6</sub> alkyl; and

R<sub>10</sub>, R<sub>11</sub>, X, Y and Z are independently selected from hydrogen, halogen, hydroxy, amino, mono- and di(C<sub>1</sub>-C<sub>6</sub>)alkyl amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy.

Claim 13. (Currently Amended) A method according to claim 8 ~~of~~ where the compound has the formula:



or a pharmaceutically acceptable salt thereof, wherein:

m is 1, 2, or 3;

R represents up to 5 groups independently chosen from hydrogen, halogen, hydroxy, amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy;


R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently chosen from (i) hydrogen; and (ii) C<sub>1</sub>-C<sub>6</sub> acyl and C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted with up to three substituents independently chosen from halogen,

hydroxy, halo(C<sub>1</sub>-C<sub>2</sub>)alkyl, halo(C<sub>1</sub>-C<sub>2</sub>)alkoxy, methoxy, ethoxy, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, phenyl, pyridyl and pyrimidyl, wherein each of phenyl, pyridyl and pyrimidyl is optionally substituted with up to three groups selected independently from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy and amino;

R<sub>6</sub> and R<sub>6</sub>' are independently chosen from hydrogen, methyl, and ethyl; and

R<sub>10</sub>, R<sub>11</sub>, X, Y and Z are independently selected from hydrogen, halogen, hydroxy, amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy.

Claim 14. (Currently Amended) A method according to claim 13 ~~of~~ where the compound has the formula:



or a pharmaceutically acceptable salt thereof, wherein:

R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently chosen from (i) hydrogen; and (ii) C<sub>1</sub>-C<sub>6</sub> acyl and C<sub>1</sub>-C<sub>6</sub> alkyl, optionally substituted with up to three substituents independently chosen from halogen, hydroxy, halo(C<sub>1</sub>-C<sub>2</sub>)alkyl, halo(C<sub>1</sub>-C<sub>2</sub>)alkoxy, methoxy, ethoxy, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, phenyl, pyridyl and pyrimidyl, wherein each of phenyl, pyridyl and pyrimidyl is optionally substituted with up to three groups selected independently from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy and amino;

R<sub>10</sub>, R<sub>11</sub>, X, Y and Z are selected from hydrogen, halogen, hydroxy, amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy.

Claim 15. (previously presented) A method according to claim 14, wherein:

R<sub>3</sub> is hydrogen, methyl or ethyl;

R<sub>4</sub> and R<sub>5</sub> are independently C<sub>2</sub>-C<sub>6</sub> alkyl; and

R<sub>10</sub>, R<sub>11</sub>, X, W, Y and Z are independently hydrogen, halogen or methyl.

Claim 16. (previously presented) A method according to claim 11, wherein:

n is 1; and

R<sub>1</sub> and R<sub>2</sub> are independently chosen from hydrogen, halogen, hydroxy, amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy.

Claim 17. (previously presented) A method according to claim 16, wherein:

R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are independently chosen from hydrogen, methyl, and ethyl;

R<sub>4</sub> and R<sub>5</sub> are independently chosen from C<sub>2</sub>-C<sub>6</sub> alkyl and benzyl;

R<sub>10</sub>, R<sub>11</sub>, X, Y and Z are independently selected from hydrogen, halogen and methyl; and

R<sub>6</sub> and R<sub>6</sub>' are both hydrogen.

Claim 18. (previously presented) A method according to claim 11, wherein n is 1.

Claim 19. (previously presented) A method according to claim 18, wherein:

R<sub>1</sub> and R<sub>2</sub> are independently chosen from hydrogen, methyl and ethyl;

R<sub>3</sub> is methyl or ethyl;

R<sub>6</sub> and R<sub>6</sub>' are both hydrogen; and

R<sub>10</sub>, R<sub>11</sub>, X, W, Y and Z are independently chosen from hydrogen, halogen, methyl, and methoxy.

Claim 20. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(5-methyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-propyl(3-fluorophenyl)carboxamide.

Claim 21. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4,5-dimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo [1,5a] pyrimidin-2-yl))methyl]- N-propyl(3-fluorophenyl)carboxamide.

Claim 22. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(5-methyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(3-fluorophenyl)carboxamide.

Claim 23. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4,5-dimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(3-fluorophenyl)carboxamide.

Claim. 24. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-4,5-dimethyl-7-oxo(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(3-fluorophenyl)carboxamide.

Claim 25. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4-ethyl-5-methyl-7-oxo-3-



propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl)methyl]-N-propyl(3-fluorophenyl)carboxamide.

Claim 26. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-5,6-dimethyl-7-oxo(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl)methyl)-N-propyl(3-fluorophenyl)carboxamide.

Claim 27. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-4,5,6-trimethyl-7-oxo(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl)methyl)-N-propyl(3-fluorophenyl)carboxamide.

Claim 28. (Currently Amended) A method according to claim 1, which is N-[(4,5-dimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl)methyl)-N-(methylpropyl)(3-fluorophenyl)carboxamide.

Claim 29. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4,5-dimethyl-7-oxo-3-propyl(4,7a-dihydropyrazolo[1,5a]pyrimidin-2-yl)methyl)-N-(ethylpropyl)(3-fluorophenyl)carboxamide.

Claim 30. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4,5-dimethyl-7-oxo-3-propyl(4,7a-dihydropyrazolo[1,5a]pyrimidin-2-yl)methyl)-N-benzyl(3-fluorophenyl)carboxamide.

Claim 31. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(5,6-dimethyl-7-oxo-3-propyl(4,7a-dihydropyrazolo[1,5a]pyrimidin-2-yl)methyl)-N-propyl(3-fluorophenyl)carboxamide.

Claim 32. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-propyl-N-[(4,5,6-trimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl](3-fluorophenyl)carboxamide.

Claim 33. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-5-methyl-7-oxo(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(3-chlorophenyl)carboxamide.

Claim 34. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-4,5-dimethyl-7-oxo(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(3-chlorophenyl)carboxamide.

Claim 35. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4,5-dimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-(methylpropyl)(3-chlorophenyl)carboxamide.

Claim 36. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4,5-dimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-(ethylpropyl)(3-chlorophenyl)carboxamide.

Claim 37. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4,5-dimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-benzyl(3-chlorophenyl)carboxamide.

Claim 38. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(5,6-dimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-propyl(3-chlorophenyl)carboxamide.

Claim 39. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-propyl-N-[(4,5,6-trimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl](3-chlorophenyl)carboxamide.

Claim 40. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(5-methyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(2,5-difluorophenyl)carboxamide.

Claim 41. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4,5-dimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(2,5-difluorophenyl)carboxamide.

Claim 42. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-ethyl-N-[(3-ethyl-5-methyl-7-oxo(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl](2,5-difluorophenyl)carboxamide.

Claim 43. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-4,5-dimethyl-7-oxo(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(2,5-difluorophenyl)carboxamide.

Claim 44. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4,5-dimethyl-7-oxo-3-

propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl)methyl]-N-(methylpropyl)(2,5-difluorophenyl) carboxamide.

Claim 45. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4,5-dimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl)methyl)-N-(ethylpropyl)(2,5-difluorophenyl)carboxamide.

Claim 46. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4,5-dimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl)methyl)-N-benzyl(2,5-difluorophenyl)carboxamide.

Claim 47. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(5,6-dimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo[1,5a]pyrimidin-2-yl)methyl)-N-propyl(2,5-difluorophenyl)carboxamide.

Claim 48. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-propyl-N-[(4,5,6-trimethyl-7-oxo-3-propyl(4,7-dihydropyrazolo [1,5a]pyrimidin-2-yl)methyl](2,5-difluorophenyl)carboxamide.

Claim 49. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(7-methoxy-5-methyl-3-propyl(pyr azolo[1,5-a]pyrimidin-2-yl)methyl)-N-(2-methylpropyl)(3-fluorophenyl) carboxamide.

Claim 50. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(7-methoxy-5-methyl-3-propyl(pyr azolo[1,5-a]pyrimidin-2-yl)methyl)-N-propyl(3-fluorophenyl)carboxamide.

Claim 51. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-7-methoxy-5-methyl(pyrazolo[1,5-a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(3-fluorophenyl) carboxamide.

Claim 52. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-7-methoxy-5-methyl(pyrazolo[1,5-a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(3-chlorophenyl) carboxamide.

Claim 53. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(7-methoxy-5-methyl-3-propyl(pyrazolo[1,5-a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(2,5-difluorophenyl) carboxamide.

Claim 54. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-7-methoxy-5-methyl(pyrazolo[1,5-a]pyrimidin-2-yl))methyl]-N-(2-methylpropyl)(2,5-difluorophenyl) carboxamide.

Claim 55. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(8-oxo-3-propyl(4,5,6,7,8a-pentahydrocyclopenta[2,1-d]pyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-propyl(3-fluorophenyl) carboxamide.

Claim 56. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(4-methyl-8-oxo-3-propyl(4,5,6,7,8a-pentahydrocyclopenta[2,1-d]pyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-propyl(3-fluorophenyl) carboxamide.

Claim 57. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-8-oxo(4,5,6,7,8a-pentahydrocyclopenta[2,1-d]pyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-propyl(3-fluorophenyl) carboxamide.

Claim 58. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-4-methyl-8-oxo(4,5,6,7,8a-pentahydrocyclopenta[2,1-d]pyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-propyl(3-fluorophenyl) carboxamide.

Claim 59. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-8-oxo(4,5,6,7,8a-pentahydrocyclopenta[2,1-d]pyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-propyl(3-chlorophenyl) carboxamide.


Claim 60. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-4-methyl-8-oxo(4,5,6,7,8a-pentahydrocyclopenta[2,1-d]pyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-propyl(3-chlorophenyl) carboxamide.

Claim 61. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-8-oxo(4,5,6,7,8a-pentahydrocyclopenta[2,1-d]pyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-propyl(2,5-difluorophenyl) carboxamide.


Claim 62. (Currently Amended) A method according to claim 1, ~~which~~ where the compound is N-[(3-ethyl-4-methyl-8-oxo(4,5,6,7,8a-pentahydrocyclopenta[2,1-d]pyrazolo[1,5a]pyrimidin-2-yl))methyl]-N-propyl(2,5-difluorophenyl) carboxamide.

Claim 63-64. (Cancelled).


Claim 65. (previously presented) A method for the treatment of anxiety, depression, a sleep disorder selected from primary insomnia, circadian rhythm sleep disorder, dyssomnia NOS, parasomnias including nightmare disorder, sleep terror disorder, sleep disorders secondary to depression, anxiety and/or other mental disorders and substance-induced sleep disorder, or attention deficit disorder, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula I where Formula I is




or a pharmaceutically acceptable salt thereof, wherein n is 1, 2, or 3;



represents



or



;

R<sub>1</sub> and R<sub>2</sub> are independently chosen from hydrogen, halogen, hydroxy, amino, mono- and di(C<sub>1</sub>-C<sub>6</sub>)alkyl amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy; or R<sub>1</sub> and R<sub>2</sub> together with the atoms with which they are attached form a partially saturated or unsaturated carbocyclic ring of from 3 to 8 carbon atoms, wherein the ring is optionally substituted by up to 5 substituents independently chosen from halogen, hydroxy, amino, mono- and di(C<sub>1</sub>-C<sub>6</sub>)alkyl amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy;

R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently chosen from hydrogen; C<sub>1</sub>-C<sub>6</sub> acyl; and C<sub>1</sub>-C<sub>6</sub> alkyl; wherein each C<sub>1</sub>-C<sub>6</sub> acyl and C<sub>1</sub>-C<sub>6</sub> alkyl is optionally substituted with up to three substituents independently chosen from halogen, hydroxy, halo(C<sub>1</sub>-C<sub>2</sub>)alkyl, halo(C<sub>1</sub>-C<sub>2</sub>)alkoxy, methoxy, ethoxy, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, phenyl, pyridyl, and pyrimidyl, wherein each of phenyl, pyridyl, and pyrimidyl is optionally substituted with up to three groups independently selected from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, hydroxy and amino;

R<sub>6</sub> and R<sub>6</sub>' are independently selected at each occurrence from hydrogen and C<sub>1</sub>-C<sub>6</sub> alkyl;

W is aryl or heteroaryl, each of which is optionally substituted with up to 5 groups independently selected from hydrogen, halogen, hydroxy, amino, mono- or di(C<sub>1</sub>-C<sub>6</sub>)alkyl amino, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy.

Claims 66-78. (Cancelled)

Claim 79. (New) A method according to claim 65, wherein the treatment is for anxiety.

Claim 80. (New) A method according to claim 65, where the treatment is for depression.

Claim 81. (New) A method according to claim 65, wherein the treatment is for a sleep disorder selected from primary insomnia, circadian rhythm sleep disorder, dyssomnia NOS, parasomnias including nightmare disorder, sleep terror disorder, sleep disorders secondary to depression, anxiety and/or other mental disorders and substance-induced sleep disorder.



Claim 82. (New) A method according to claim 65, where the treatment is for attention deficit disorder.